NeuroScientific

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?
January 14, 2026

ASX defence stocks

Trump’s Venezuela Strike Puts These 3 ASX Defence Stocks in Focus
January 6, 2026